Next Article in Journal
Metabolic Profiles of Brain Metastases
Next Article in Special Issue
Amplification Target ADRM1: Role as an Oncogene and Therapeutic Target for Ovarian Cancer
Previous Article in Journal
Blood microRNAs in Low or No Risk Ischemic Stroke Patients
Previous Article in Special Issue
Hedgehog Signaling Pathway in Ovarian Cancer
Open AccessArticle

Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening

1
Department of Obstetrics and Gynaecology, Trinity College Dublin, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland
2
Department of Histopathology, Trinity College Dublin, Sir Patrick Duns Research Laboratory, St. James's Hospital and The Coombe Women and Infants University Hospital, Dublin 8, Ireland
3
Department of Clinical Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St. James's Hospital, Dublin 8, Ireland
4
Department of Histopathology, St. James's Hospital, Dublin 8, Ireland
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2013, 14(1), 2085-2103; https://doi.org/10.3390/ijms14012085
Received: 7 November 2012 / Revised: 5 January 2013 / Accepted: 6 January 2013 / Published: 22 January 2013
(This article belongs to the Special Issue Genes and Pathways in the Pathogenesis of Ovarian Cancer)
Platinum resistance is a major cause of treatment failure in ovarian cancer. We previously identified matrix metalloproteinase 9 (MMP-9) as a potential therapeutic target of chemoresistant disease. A2780cis (cisplatin-resistant) and A2780 (cisplatin-sensitive) ovarian carcinoma cell lines were used. The cytotoxic effect of MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) alone or in combination with cisplatin was determined using high content screening. Protein expression was examined using immunohistochemistry and ELISA. Co-incubation of cisplatin and an MMP-9/MMP-2 inhibitor, (2R)-2-[(4-Biphenylsulfonyl) amino]-3 phenylpropionic acid (C21H19NO4S) resulted in significantly greater cytotoxicity as compared to either treatment alone in a cisplatin resistant MMP-9 overexpressing cell line; A2780cis. In addition, pre-incubating with MMP-9i prior to cisplatin further enhances the cytotoxic effect. No significant difference was observed in MMP-9 protein in tissue but a trend towards increased MMP-9 was observed in recurrent serum. We propose that MMP-9/MMP-2i may be utilized in the treatment of recurrent/chemoresistant ovarian cancers that overexpress MMP-9 mRNA but its role in vivo remains to be evaluated. View Full-Text
Keywords: ovarian; MMP-9/MMP-2 inhibitor; chemoresistance; recurrent; high content screening ovarian; MMP-9/MMP-2 inhibitor; chemoresistance; recurrent; high content screening
Show Figures

Graphical abstract

MDPI and ACS Style

Laios, A.; Mohamed, B.M.; Kelly, L.; Flavin, R.; Finn, S.; McEvoy, L.; Gallagher, M.; Martin, C.; Sheils, O.; Ring, M.; Davies, A.; Lawson, M.; Gleeson, N.; D'Arcy, T.; D'Adhemar, C.; Norris, L.; Langhe, R.; Saadeh, F.A.; O'Leary, J.J.; O'Toole, S.A. Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. Int. J. Mol. Sci. 2013, 14, 2085-2103. https://doi.org/10.3390/ijms14012085

AMA Style

Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, D'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA. Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. International Journal of Molecular Sciences. 2013; 14(1):2085-2103. https://doi.org/10.3390/ijms14012085

Chicago/Turabian Style

Laios, Alexandros; Mohamed, Bashir M.; Kelly, Lynne; Flavin, Richard; Finn, Stephen; McEvoy, Lynda; Gallagher, Michael; Martin, Cara; Sheils, Orla; Ring, Martina; Davies, Anthony; Lawson, Margaret; Gleeson, Noreen; D'Arcy, Tom; D'Adhemar, Charles; Norris, Lucy; Langhe, Ream; Saadeh, Feras A.; O'Leary, John J.; O'Toole, Sharon A. 2013. "Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening" Int. J. Mol. Sci. 14, no. 1: 2085-2103. https://doi.org/10.3390/ijms14012085

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop